Freed AI Medical Scribe vs Owkin
Detailed side-by-side comparison to help you choose the right tool
Freed AI Medical Scribe
🟢No CodeHealthcare AI
AI medical scribe and front-desk assistant for clinicians, specialty notes, coding support, and EHR workflows.
Was this helpful?
Starting Price
CustomOwkin
Healthcare AI
Owkin is a full-stack AI biotech company using federated learning to train machine learning models on hospital data without centralizing patient records. Founded in 2016 and headquartered in Paris, Owkin has raised over $300M in funding, secured a strategic partnership with Sanofi valued at over $180M, and developed MSIntuit CRC—an FDA-cleared AI diagnostic for detecting microsatellite instability in colorectal cancer from standard pathology slides. The company operates the MOSAIC federated learning platform across 15+ academic medical centers worldwide and offers the K Pro AI Scientist for pharma decision-making across clinical trial, patient, and portfolio decisions.
Was this helpful?
Starting Price
CustomFeature Comparison
Scroll horizontally to compare details.
Freed AI Medical Scribe - Pros & Cons
Pros
- ✓Transparent entry pricing starting at $39/month for AI scribe
- ✓Built for individual clinicians and community practices rather than only large health systems
- ✓7-day free trial with no credit card needed
- ✓EHR push, coding support, and patient letters reduce more than transcription work
Cons
- ✗Static HTML showed alternate dollar figures, so exact billing display should be verified live
- ✗Clinicians must still review every note and coding suggestion
- ✗EHR push is described as beta for integrations agent, so reliability should be tested
- ✗May not have the enterprise deployment depth of health-system-focused vendors
Owkin - Pros & Cons
Pros
- ✓Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
- ✓FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
- ✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
- ✓Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
- ✓Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
- ✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms
Cons
- ✗Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
- ✗Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
- ✗Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
- ✗No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
- ✗Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
- ✗Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines
Not sure which to pick?
🎯 Take our quiz →Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.
Ready to Choose?
Read the full reviews to make an informed decision